Kornimate/medical-research-clean huggingface dataset:
schizophrenia treatment with electric transcranial stimulation

Conditions: Schizophrenia

Summary: the aim of this study is to evaluate the therapeutic efficacy of tdcs (transcranial direct current stimulation) for treatment of negative symptoms in patients with schizophrenia. the proposed design is a clinical trial, randomized, double-blind, placebo-controlled study. participants will receive ten sessions of active or sham stimulation in five consecutive days. 100 patients will be randomized into two groups (active tdcs vs sham tdcs) and will be assessed after the intervention: 2, 4, 6 and 12 weeks after. as objectives, the investigators expect to see a clinical improvement of negative symptoms through scales panss (positive and negative syndrome scale), calgary, auditory verbal hallucinations, sans (skills for assessment of negative symptoms), and expect improvement on computerized cognitive tests. another goal is to see improvement in biological markers related to schizophrenia, plasma and dna will be stored.


Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia according to dsm-iv criteria and confirmed by the scid * minimum score of 20 points in the sum of negative panss * stable antipsychotic medications exclusion criteria: * unstable medical illness * uncontrolled pretreatment with rtms or tdcs * at least six months without being in ect * benzodiazepines in doses of 10mg of diazepam * electronic or metal implants in the cephalic segment. * other mental disorders and dependence of substances

Keywords: schizophrenia transcranial stimulation
characterizing the effects of family history of alcoholism on alcohol analgesia

Conditions: Effects of Family History of Alcoholism and Sex on Alcohol Analgesia

Summary: self-medication of pain with alcohol is a common, yet risky, behavior. evidence suggests family history of alcoholism may affect the degree to which alcohol use relieves pain, but the independent contributions of expectation and conditioning have not been previously studied. interactive effects of sex and family history are also currently unclear. this project addresses this gap in knowledge and will inform further research and clinical/translational efforts for reducing risk associated with these behaviors.


Eligibility criteria:
inclusion criteria: - consume at least 1 drink/month over the past 6 months exclusion criteria: * history of chronic pain * current use of opioids * current major depression * history of any psychotic disorder * undercontrolled hypertension or diabetes * history of neurologic disease * history of serious medical illness * history of drug or alcohol dependence, including nicotine, or a pattern of hazardous alcohol use * safety concerns related to mri (for example, implants or pacing devices)

Keywords: alcohol effects pain
"using a multisite tens system to improve fibromyalgia-related symptoms.

Conditions: Fibromyalgia, Pain

Summary: fibromyalgia is a debilitating pain condition that is characterized by the chronic occurrence of pain affecting the musculoskeletal system, a sensitivity to pressure stimuli, and a low threshold to noxious stimuli. the topography of pain is widespread, although it could be more pronounced in some bodily regions. besides pain, patients suffer from a wide range of symptoms, including fatigue, anxiety and depression manifestations, and altered quality of life. facing these debilitating symptoms, the available therapeutic strategies for treating pain and associated manifestations are usually faced with limited efficacy and numerous side effects. a previous pilot trial on fibromyalgia (exofib-1 study) was conducted to evaluate the effects of exopulse mollii suit on fibromyalgia has showed beneficial and promising results. the intervention significantly alleviated pain, reduced fatigue, decreased physical and psychosocial impact of the disease, and improved the quality of life of patients with fibromyalgia. however, the observed effect sizes were small to medium. the investigators believe that a stimulation duration extended to six months would yield more positive outcomes and higher effect magnitude.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 75 years, with a definite diagnosis of fibromyalgia according to the american college of rheumatology (acr) 2010 criteria, set for at least three months * patients should be french speakers, able to understand verbal instructions, and affiliated with the national health insurance exclusion criteria: * patient included in another research protocol during the study period * patient unable to undergo medical monitoring for the study purposes due to geographical or social reasons * patient with contraindication to wearing exopulse mollii suit (e.g., cardiac stimulator, a ventriculoperitoneal shunt, intrathecal baclofen pump, pregnancy, and/or body mass index above 35 kg/m2) * patient with somatic or psychiatric diagnoses other than anxiety and depression (e.g., arrhythmias, uncontrolled epilepsy, other diseases causing osteoarticular and muscular pain) * any change in the pharmacological therapy in the last three months * introduction of a medical device other than exopulse mollii suit during the study period * patient under juridical protection (" mesure de protection judiciare : tutelle, curatelle, sauvegarde de justice ")

Keywords: exopulse mollii suit, fibromyalgia
mollii suit and fibromyalgia (exofib 2)

Conditions: Fibromyalgia; Rheumatic Diseases; Muscular Diseases; Neuromuscular Diseases; Nervous System Diseases

Summary: the goal of this clinical trial is to demonstrate the improvement of fibromyalgia syndrome obtained following active stimulation compared to sham, with diminished functional disability and improved health status using exopulse molli suit stimulation. the main questions it aims to answer are: evaluation of pain, fatigue, mood and quality of life changes observed after active stimulation in comparison to sham. improvement of fibromyalgia syndrome as per the fibromyalgia impact questionnaire (fiq) study subjects will participate in: a randomized sham controlled double-blind trial to demonstrate the improvement of pain, quality of life, fatigue and mood in adult patients with fibromyalgia following a 2-week intervention of "active" versus "sham" exopulse mollii suit. a 2-week washout period should be enough to prevent a potential carry over effect. after this phase (phase 1), a second open label phase (phase 2) will be proposed for patients to understand the effects of exopulse mollii suit employed for 4 weeks (7 sessions per week) on the studied outcomes.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 75 years, with a definite diagnosis of fibromyalgia according to the american college of rheumatology (acr) 2010 criteria, set for at least one month. * patients should be able to understand verbal instructions. exclusion criteria: * patient with vas \< 4 * patient included in another research protocol during the study period * patient unable to undergo medical monitor for the study purposes due to geographical or social reasons * patient with contraindication to wearing exopulse mollii suit (e.g., cardiac stimulator, a ventriculoperitoneal shunt, intrathecal baclofen pump, pregnancy, and/or body mass index above 35 kg/m2) * patient with other somatic or psychiatric diagnoses other than anxiety and depression (e.g., arrhythmias, uncontrolled epilepsy, other diseases causing osteoarticular and muscular pain) * any change in the pharmacological therapy in the last three months * introduction of a medical device other than exopulse mollii suit during the study period * patient under juridical protection
individual differences in glucosamine sulfate exposure levels

Conditions: Knee Osteoarthritis

Summary: glucosamine is an important part of the treatment strategy for osteoarthritis, but its effectiveness is still controversial. to explain the efficacy differences of glucosamine, in this study the investigators detect the concentration of glucosamine in the plasma and synovial fluid, some effect indexes such as inflammatory markers and gene polymorphism of glucosamine transporters. on the one hand, the investigators compare the plasma peak and gluten glucosamine concentration and the concentration in synovial fluid among participants to observe the individual differences of glucosamine exposure in vivo. on the other hand, the investigators investigate the correlation between drug concentrations, effect index and gene polymorphism. the hypothesis is that glucosamine exposure in vivo has individual differences and gene polymorphism can explain this differences.


Eligibility criteria:
inclusion criteria: 1. patients undergoing total knee arthroplasty for knee osteoarthritis; 2. 60-80 years. exclusion criteria: 1. patients with severe liver or renal insufficiency; 2. patients allergic to glucosamine or any excipients in tablets; 3. patients who have been treated with glucosamine within three months; 4. patients who are unable to cooperate with the study; 5. continuous medication is less than 4 days; 6. patients with diarrhea, vomiting and other adverse reactions during medication.

Keywords: glucosamine sulfate individual differences gene polymorphism
tapp inguinal hernia repair with self-fixating parietex™ progrip™ mesh

Conditions: Postoperative Complications

Summary: the objective of this retrospective study is to evaluate the postoperative clinical outcomes at discharge, 1 month and 12 months, associated with the use of parietex™ progrip™ in laparoscopic transabdominal preperitoneal inguinal hernia repair. results from this study will be used to support the short- and long-term clinical outcomes of parietex™ progrip™ when used in inguinal hernia repair by laparoscopic approach. * single center study * population: all subjects have undergone laparoscopic transabdominal preperitoneal surgical treatment for inguinal hernia repair with parietex™ progrip™ without additional fixation between september 2008 and march 2010 (inclusive) with at least 12 months of follow-up. the primary outcome: • proportion of subjects who experience hernia recurrence (defect treated initially with parietex™ progrip™) within 12 months post-surgery. recurrence is defined as a clinically manifest bulge or a protrusion exacerbated by a valsalva maneuver in the operated groin. the recurrence symptoms are assessed by phone based on the symptoms questionnaire and the recurrence diagnosis is confirmed during a physical examination by a physician and defined as a clinically manifest bulge or a protrusion exacerbated by a valsalva maneuver in the operated groin. if subject has a surgical repair of the hernia within the 12 month postoperative period, it will be documented as evidence of hernia recurrence. the secondary outcome: * incidence of groin pain (pain score 0-10) and analgesic use at discharge, 1 month and 12 month postoperatively * incidence of postoperative complications including, wound infection (any infection of the incision), mesh infection (an infection of the mesh), bleeding, mesh migration, mesh erosion, fistula, small bowel obstruction, seroma, hematuria, hematoma, inflammation, chronic pains/ inguinodynia, infection, visceral adherence, allergic reactions to the components of the product at discharge, 1month and 12 month post-operatively * patient satisfaction * operative time * hospital length of stay


Eligibility criteria:
inclusion criteria: * the following diagnosis will be included: * inguinal hernia: unilateral or bilateral all subjects must meet the following inclusion criteria: * ≥18 years of age * had undergone elective (non-emergent) primary surgical repair of the above diagnosis with parietex progrip™ by laparoscopic transabdominal preperitoneal inguinal hernia repair between september 2008 to march 2010 * post-operative follow-up ≥ 12 months or recurrence which occurs within the 12 months post-surgery (if subject has a known incidence of recurrence before the 12 months follow up, the subject will be included in the study.) exclusion criteria: * subjects who meet any of the following exclusion criteria are not eligible for study participation: * patients with previous laparoscopic inguinal hernia repair * emergency procedures * patients with incarcerated hernias

Keywords: parietex™ progrip™ laparoscopic transabdominal preperitoneal tapp inguinal hernia repair
ultrasound evaluation of the myometrium using the musa terminology comparison with histology

Conditions: Myoma;Uterus; Sarcoma Uterus

Summary: the main objective is to evaluate the diagnostic accuracy of the musa terms and definitions, as defined in the paper by van den bosch t, dueholm m, ea. in 2015, to differentiate between different types of myometrial lesions of more than 1 cm. the primary aim is the diagnostic accuracy of the musa terms and definitions and the secondary aim the development of a prediction model.

primary aim: diagnostic accuracy of the musa terms and definitions every patient planned for hysterectomy for myometrial pathology (e.g. benign fibroid, benign adenomyoma or malignant uterine sarcoma) will undergo a systematic preoperative ultrasound scan. around 50 ultrasound characteristics will be assess as to diagnostic accuracy as predictors (prospective evaluation of musa terms and definitions). the estimation for sarcomas is based on preliminary and unpublished results from an ongoing prospective study led by prof dr antonia testa from the università cattolica di sacro cuore largo agostino gemelli in rome showing an incidence of 4.9% for uterine sarcomas amongst women with a myometrial lesion referred to their tertiary center (antonia testa, personal communication). secondary aim: development of prediction model the secondary aim is to build predictive models to differentiate between benign myometrial lesions (e.g. adenomyosis and fibroid) and malignant myometrial lesion (e.g. uterine sarcoma). because of the small number of cases with malignant myometrial lesion (expected to be 5% of the study population or around 75 women), we will limit the number of variables to be tested in order to avoid overfitting. based on current literature, we preselected following characteristics for development of a prediction model: * outer contour: regular of irregular * echogenicity of uterine lesion: uniform (homogeneous) or non-uniform (mixed) * colour score: 1 to 4 * presence of central necrosis * maximal diameter of the lesion (in mm) * presence of acoustic shadows

Eligibility criteria:
inclusion criteria: consecutive patients planned to undergo hysterectomy for myometrial pathology of more then 1cm (e.g. fibroid, focal adenomyosis, uterine sarcoma). exclusion criteria: * patient's refusal * age \< 18 years * polymyomatous uterus * myometrial lesion with a diameter less then 10mm * patients currently treated for another cancer * patients with ovarian pathology, endometrial pathology of cervical pathology * power morcellation
an istitution experience on parosteal osteosarcoma

Conditions: Parosteal Osteosarcoma

Summary: single institution cases series review of histological and clinical data

investigators will review all the cases with a diagnosis of primary parosteal osteosarcoma treated at the rizzoli institute from 1900 up to 31 july 2018, retrospectively.

Eligibility criteria:
inclusion criteria: * male and female patients treated at rizzoli institute from 01 jan 1900 to 31 jul 2018 * diagnosis of parosteal osteosarcoma * written informed consent prior to any study-specific analysis and/or data collection exclusion criteria: • patients with histological diagnosis different from parosteal osteosarcoma
acoart avf renew: a post market clinical study

Conditions: Stenosis of Native Hemodialysis Arteriovenous Fistulas

Summary: the objective of this prospective，multi-center，single arm study is to obtain further data on the safety and performance of the acotec orchid＆dhalia drug-coated balloon catheters for the treatment of for the obstructive lesions in the native arteriovenous dialysis fistulae (avf).


Eligibility criteria:
inclusion criteria: * patient is ≥18 and ≤85 years of age * the target av fistula has undergone successful dialysis for at least 1 time * patient has a de novo and/or non-stented restenotic lesion located in the outflow vein（arteries and central vein are excluded） * patient has a de novo and/or non-stented restenotic lesion（≥50% stenosis）and at least one of the following occurs： * the physical examination was abnormal * significant increase in dynamic venous pressure * blood flow decreased significantly * patient has a target lesion or a tandem lesion that is ≤ 100 mm in length * patient underwent successful crossing of the target lesion with the guide wire and pre-dilatation with a pta balloon defined as: * residual stenosis of ≤ 30% and * absence of a flow limiting dissection (grade ≥c) or perforation * patient provides written informed consent prior to enrollment in the study exclusion criteria: * women who are breastfeeding, pregnant, or are intending to become pregnant, or men intending to father children * dialysis access is located in the lower extremity * more than one lesion * patient with hemodynamically significant central venous stenoses * patient has presence of a stent located in the target av access circuit * patient has undergone prior intervention of access site within 30 days of index procedure * patient with target avf or access circuit which previously had or currently has a plan to surgery * patient who cannot receive recommended antiplatelet and/or anticoagulant therapy * patients undergoing immunotherapy or suspected/confirmed vasculitis * patients with a history of coagulation dysfunction, thrombocytopenic purpura or rh-negative blood type * patient has an infected av access or systemic infection * patient has a life expectancy of \<24 months * patient is anticipating a kidney transplant or with anticipated conversion to peritoneal dialysis * patient has a co-morbid condition that, in the judgment of the investigator, may cause him/her to be non-compliant with the protocol or confound the data interpretation * patient is enrolled in another investigational drug, device, or biologic study and has not completed the primary endpoint, or was previously enrolled in this study
a multicenter comparative trial of zonisamide and topiramate as initial monotherapy in untreated epilepsies

Conditions: Epilepsy

Summary: to assess the efficacy and safety of zonisamide and topiramate as initial monotherapy in untreated epilepsies


Eligibility criteria:
inclusion criteria: 1. patients over 13 years old (complete the elementary school course). 2. patients had at least two seizures in the past and at least one seizure for the last 3 months before screening. 3. patients had no antiepileptic drugs for the last 4 months. 4. women of childbearing age who agree to contraception during participating this clinical trial. exclusion criteria: 1. pregnancy 2. patients who have progressive neurologic disease 3. allergy to sulfonamides 4. use of acetazolamide within a year 5. hemolytic anemia 6. patients who have abnormal liver function (got or gpt) values more than twice the normal values. 7. patients who have abnormal renal function (bun or creatinine) values more than three times the normal values. 8. patients who have history of drug or alcohol abuse. 9. glucose-6-phosphate dehydrogenase deficiency. 10. patients who were detected with renal stones on kub (kidney-ureter-bladder) test. 11. patients who have progressive internal or surgical disease. 12. patients who have progressive psychiatric disease. 13. patients who have mental retardation (iq 70 and less). 14. patients taking vit c.
a study on eradication rate of triple therapy according to treatment period and cyp2c19 polymorphisms in h.pylori patients

Conditions: Helicobacter Pylori Infection

Summary: this study compared efficacy and safety of basic triple therapy according to treatment period. this study evaluated effect of cyp2c19 genetic polymorphisms on the efficacy

this study compared efficacy and safety of basic triple therapy including noltec(ilaprazole) 10mg, clapaxine(clarithromycin) 500mg and pamoxin cap(amoxicillin) 1000mg bid on the first line eradication treatment of h.pylori according to treatment period. participants are defined as persons who have endoscopically confirmed on gastric or duodenal ulcer(including scar stage) and gastritis confirmed to be h.pylori positive patients in the ubt test. for 7 days or 10 days participants treated as basic triple therapy including noltec(ilaprazole) 10mg, clapaxine(clarithromycin) 500mg and pamoxin cap(amoxicillin) 1000mg bid. after treatment, the healing rate was evaluated in the ubt test at 49±5days from the first day dosing. the investigators would point out the impact of cyp2c19 genotypes on clarythromycin-based first-line and rescue therapies.

Eligibility criteria:
inclusion criteria: * subject must have endoscopically confirmed on gastric, duodenal ulcer(including scar) or gastritis confirmed to be h.pylori positive patients in the biopsy and ubt test. * subject who fully understands conditions of clinical trial. * subject who agrees to participate and spontaneously sign the icf exclusion criteria: * known hypersensitivity to any component of ilaprazole, amoxicillin and levofloxacin * subjects who are taking contraindicated medications for experimental and concomitant drug. * patients with abnormal levels in the laboratory tests total bilirubin, creatinine\> 1.5 times upper limit of normal ast, alt, alkaline phosphatase, bun\> 2 times upper limit of normal administrated of ppi, antibiotic medication within 4 weeks prior to commencement of the study. * pregnant and/or lactating women * reproductive aged women not using contraception * uncontrolled diabetics * uncontrolled hypertension * uncontrolled liver dysfunction * alcoholics * subjects with a history of digestive malignancy within 5 years * subjects with a history of gastrectomy or esophagectomy subjects with hereditary diseases such as galactose intolerance, lapp lactose deficiency, glucose-galactose malabsorption. * subjects participating in a clinical trial before another trial wihin 30 days * inconsistence judged subject by researcher
limitation of the ventilatory response to exercise in the master athlete

Conditions: Healthy Volunteers

Summary: it is generally accepted that the ventilatory system is not a limiting factor in physical exercise in terms of performance or exercise tolerance in healthy subjects. the ventilatory system would be oversized in relation to the stresses it has to cope with, even during maximum intensity exercise. however, some highly trained endurance athletes may be exceptions to this rule. a limitation of the expiratory flow is indeed sometimes found in these athletes, whose maximum values of ventilation can confront the mechanical limits of their ventilatory system. this phenomenon could be accentuated in elderly athletes (known as "master athletes") under the effect of structural and functional pulmonary alterations that accompany aging. our hypothesis : what is the prevalence of exercise expiratory flow limitation in the master athlete and does it cause a decrease in physical performance via an acceleration of locomotor muscle fatigue?


Eligibility criteria:
inclusion criteria: * non-smoker (active or passive) or ex-smoker of less than 5 pack-years and stopped for more than 10 years. * no known significant chronic pathology. * no symptoms suggesting a progressive pathology. * no contraindication to physical exercise. normal pulmonary functional test (pft). * participants affiliated to the social security system exclusion criteria: * vulnerable persons as defined in articles l. 1121-5 to l.1121-8 and l.1122-1-2 of the public health code (e.g. persons deprived of liberty, minors, adults protected, etc.), * participants with a medical contraindication to sports practice, * cardiovascular, respiratory, neuromuscular and/or significant metabolic, * participants with declared pathology or medical treatment, * smoking or drug use, * significant chronic drug treatment, * lack of consent. * refusal to cooperate * recent rhino-bronchial infection (within last 4 weeks) * mental disability